Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors (NCT03744468) | BeiGene | 2018-11-13 |
Track Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in automatically
Every clearance here is in the API, with alerts when new ones post.